Traders should monitor for upcoming trial data readouts on preliminary efficacy and potential Phase IIb trial initiation. Given the low market cap ($2M), any further positive clinical signal could lead to significant price volatility and potential re-rating.
Price Chart
Executive Summary
Clearmind Medicine announced that its drug candidate CMND-100 met the primary safety and tolerability endpoint in the Phase I/IIa trial for Alcohol Use Disorder, with no serious adverse events reported even at higher dosages. This milestone supports further development of the non-hallucinogenic neuroplastogen-derived therapy.
Key Facts
- CMND-100 met primary endpoint (safety and tolerability) in Phase I/IIa clinical trial for Alcohol Use Disorder.
- No serious adverse events reported, even at higher dosage in third cohort.
- Drug candidate was well tolerated with consistent safety profile across cohorts.
- Trial is multinational and multicenter, evaluating safety, pharmacokinetics, and preliminary efficacy.
- CMND-100 is a non-hallucinogenic, oral MEAI-based compound targeting a high-unmet-need indication.
Financial Impact
Potential increase in valuation due to de-risking of clinical development; no direct revenue or earnings impact yet.
Risk Factors
- Early-stage trial focused only on safety; efficacy data not yet confirmed.
- Low market cap and illiquidity increase volatility and execution risk.
- Forward-looking statements carry uncertainty; future results may differ materially.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3273236 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $5.87 (+2.17%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $5.87 (−5.78%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $5.87 (−11.06%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.87 (−11.06%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.87 (+590.59%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.87 (+590.59%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.87 (−14.48%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.87 (+521.82%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $5.87 (+469.90%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $5.87 (−406.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers